August 2013China Biologic repurchased 1,479,704 shares of common stock from one of its individual shareholders for a consideration of $29,594,080.
July 2013Guizhou Taibang received manufacturing approval certificate for Human Prothrombin Complex Concentrate ("PCC") from China Food and Drug Administration (“CFDA”).
June 2013Shandong Taibang received the renewed Good Manufacturing Practice ("GMP") certification from China Food and Drug Administration ("CFDA") in respect of its updated plasma production facility.
April 2013Shandong Taibang’s newly built plasma collection station in Cao Xian county obtained plasma collection license from the Shandong Provincial Health Department and commenced commercial plasma collection.
|FirstPage | PreviousPage | NextPage | LastPage||CurrentPageIndex：3       |